115 results about "Osseous Differentiation" patented technology

The invention discloses a KGN-carried collagen/chitosan/sodium hyaluronate composite scaffold. The scaffold is prepared from collagen, chitosan, sodium hyaluronate, KGN (kartogenin) and PLGA (poly(lactic-co-glycolic acid)). The preparation method comprises the following steps: preparing KGN-micromolecule-carried PLGA microspheres, mixing the PLGA microspheres, and preparing the collagen/chitosan/sodium hyaluronate composite scaffold. The composite scaffold has the characteristics of favorable biocompatibility, favorable biodegradability and the like, has the lubrication action of sodium hyaluronate and the marrow mesenchymal stem cell cartilage differentiation promotion action of KGN, is beneficial to cartilage defect repair of medium/early osteoarthritis, and is a favorable tissue regeneration material for osteoarthritis cartilage defects.

The invention discloses an exosome preparation derived from a stem cell. The exosome preparation is an exosome secreted by a Fe3O4 superparamagnetic nanoparticle stimulating the stem cell. The invention further provides the application of the exosome preparation in preparing a pharmaceutic preparation for promoting mesenchymal stem cell osteogenic differentiation and the application of the exosomepreparation in preparing a biological agent for treating orthopedic disorders or bone repair materials. In consideration of the complicated pathophysiologic process of osteonecrosis and bone defects,the exosome preparation prepared by the exosome secreted by the Fe3O4 superparamagnetic nanoparticle stimulating the stem cell is adopted, intramuscular administration can be adopted at local bone defect parts, or local filling is performed after the exosome preparation is mixed with absorbable gel, the exosome preparation directly reaches the focus, the osteogenic activity of the mesenchymal stem cell is motivated, the deposition of osteoblasts is promoted, and the repair of the osteonecrosis or bone defects is promoted.

According to the invention, a strong acid acidification method is combined to carry out biological functional modification on an orthopaedic biological material PEEK tablet, so that the orthopaedic biological material PEEK tablet is endowed with biological activity of inhibiting secretion of inflammatory factors while promoting osteogenic differentiation and bone mineralization of bone marrow mesenchymal stem cells. The PEEK surface modification method is simple and low in cost, and a prepared PEEK implant has multiple biological functions and is expected to promote osseointegration in a PEEKorthopaedic implant and reduce loosening-related complications caused by early excessive inflammatory response after the PEEK sheet is implanted into a body.

The invention discloses novel application of melatonin, in particular to application of a melatonin synergistic extracellular matrix biomaterial to preparation of a medicament for promoting osteoblast differentiation of mesenchymal stem cells and application of the melatonin synergistic extracellular matrix biomaterial to preparation of a medicament for treating bone diseases. Proven by experiments, by using the melatonin synergistic extracellular matrix biomaterial system, the in-vitro proliferation of the mesenchymal stem cell can be promoted, a good fibrous shape is kept for the cells, intracellular ROSs (Reactive Oxygen Species) are reduced, the epimatrix calcium deposition is facilitated, the osteogenesis gene expression is enhanced, the promotion of in-vitro osteoblast differentiation by the melatonin synergistic extracellular matrix biomaterial and a mechanism of differentiation are determined, and a basis is laid for the treatment of diseases such as osteoarthritis, bone defect and bone trauma by taking the melatonin synergistic extracellular matrix biomaterial as a repair material.

The invention provides an effect of long-chain non-coding RNA in adipogenic differentiation and osteogenic differentiation of stem cells, and belongs to the technical field of stem cells. Experimentsprove that in the adipogenic differentiation process of mesenchymal stem cells, the expression quantity of the LINC02075 is obviously increased, inhibition of LINC02075 can obviously inhibit mRNA andprotein expression of adipogenic differentiation related genes PPAR gamma, C/EBP alpha and AP2, thereby inhibiting the adipogenic differentiation of the mesenchymal stem cells. Meanwhile, the invention proves that inhibition of LINC02075 can significantly promote mRNA and protein expression of osteogenic differentiation related genes RUNX2, ALP and OCN to promote osteogenic differentiation of themesenchymal stem cells

The invention discloses a method for promoting osteogenic differentiation of bone marrow mesenchymal stem cells. The method comprises the following steps of (1) culturing human bone marrow mesenchymalstem cells in a DMEM/F12 medium, and performing digestion with 0.25% pancreatin for passage when the cell fusion degree reaches 80-90%; and (2) inoculating a differential medium with the bone marrowmesenchymal stem cells obtained by subculture in the step (1), and carrying out induced differentiation, wherein the differential medium comprises the DMEM/F12 medium, 18-22 [mu]g/mL of insulin, 5-10ng/mL of dexamethasone, 40-50 [mu]g/mL of ascorbic acid, 15-23 [mu]g/mL of sulfobutyl-beta-cyclodextrin, 45-52 [mu]g/mL of betaine, 10-15 ng/mL of indium acetate and 50-60 [mu]g/mL of glutathione. According to the invention, the differential medium is inoculated with the bone marrow mesenchymal stem cells obtained through subculture, and the sulfobutyl-beta-cyclodextrin, the betaine and the indiumacetate are added into the differential medium to achieve a synergistic effect, so that the osteogenic differentiation efficiency of the bone marrow mesenchymal stem cells is effectively improved, the osteogenic differentiation time is shortened, and a guarantee is provided for clinical application of the bone marrow mesenchymal stem cells to tissue-engineered bone construction.

The invention provides an iodine-loaded titanium alloy implant with functions of resisting bacteria and promoting osteogenic differentiation and mineralization, and a preparation method of the iodine-loaded titanium alloy implant. According to the preparation method, an iodine coating is fixed to a titanium alloy through a covalent grafting and redox reaction method, the prepared iodine coating titanium sheet shows antibacterial performance, can promote osteogenic differentiation of bone marrow mesenchymal stem cells, and can promote generation of a calcium phosphorylation layer in simulated body fluid. The preparation process provided by the invention is simple and feasible, has the advantages of high efficiency, low cost and good repeatability, and can effectively improve clinical defects of an existing titanium alloy implant applied to the orthopedics department, the oral and maxillofacial surgery department and the neurosurgery department can be effectively overcome, so that the occurrence rate of postoperative early infection after the titanium alloy implant is implanted into a body can be reduced, and related complications such as implant looseness caused by excessive inflammatory reaction is reduced.

The invention provides application of melatonin in preparation of a medicine for preventing premature senility of mesenchymal stem cells; the mesenchymal stem cells are mesenchymal stem cells obtained from human, pig, mouse or rabbit tissues; influence of the melatonin to the multiplication capacity of premature senility mesenchymal stem cells is detected by using CCK-8; change of the SA-beta-Gal dyeing positive rate after the melatonin acts on the premature senility mesenchymal stem cells is detected and analyzed by using SA-beta-Gal dyeing; change of the cell cycle after the melatonin acts on the premature senility mesenchymal stem cells is detected and analyzed by using a flow cytometry; dyeing is carried out by using calcium nodule alizarin red; and influence of the melatonin to the osteogenesis ability of the premature senility mesenchymal stem cells is quantitatively detected and analyzed by using calcium nodule. Application disclosed by the invention provides a policy for preventing oxidative stress injury through cell therapy based on the mesenchymal stem cells.

The invention discloses circRNA-FTO for regulating and controlling ADSCs osteogenic differentiation and tissue regeneration and application of the circRNA-FTO and belongs to the technical field of bone tissue regeneration. The circRNA-FTO circbase ID is has-circ-0005941, the cDNA sequence is as shown in SEQ ID NO: 1, and the sequence is a cyclic structure formed by connecting the sequences as shown in the sequence end to end. In-vivo and in-vitro experiments of regulating ADSCs osteogenic differentiation and tissue regeneration by the circRNA-FTO prove that the circRNA-FTO plays an important regulating role in the adipose-derived stem cell osteogenic differentiation and/or tissue regeneration process; the circRNA-FTO can be used as a potential target for tissue regeneration treatment, newcircRNA-FTO related drugs or factors are promoted to be developed, and finally the circRNA-FTO related drugs or factors are applied to the field of regenerative medicine, so that real clinical precision medical treatment is achieved.

The invention relates to a method for improving osteogenic differentiation efficiency of human amniotic mesenchymal stem cells. The method adds an induction composition in the human amniotic mesenchymal stem cells, wherein the composition comprises 0.1-2g/L of hyaluronic acid, 0-200mg/L of prostaglandin receptor-2 selective agonist, 1-100nmol/L of dexamethasone, 0-10nmol/L of beta-glycerophosphate and 1-100mg/L of ascorbic acid. Compared with a conventional inducing method, the osteogenic differentiation efficiency of the human amniotic mesenchymal stem cells can be significantly improved, expression and activity of alkaline phosphatase are promoted, and expression of osteogenesis-related genes of RunX2, Osx, BSP, Ocn, ALP, Col1a1 and the like and formation of mineralized calcium nodules are enhanced. The method for improving the osteogenic differentiation efficiency of the human amniotic mesenchymal stem cells can be applied in osteogenic differentiation of the human mesenchymal stem cells, and applied in bone diseases of bone defects, bone trauma and the like.

The invention belongs to the technical field of bone tissue engineering, and particularly relates to a method for promoting osteogenic differentiation of mesenchymal stem cells and application. The invention provides the method for promoting osteogenic differentiation of the mesenchymal stem cells (MSCs), that is, N-acetyltransferase 10 (NAT10) is overexpressed in vivo by a biological method, through overexpression of NAT10 in mice by adenovirus according to the method, it is found that NAT10 can reverse bone mass loss of osteoporosis mice, enhance osteogenic differentiation potential of the MSCs, effectively increase local bone mass, increase bone mineral density, enhance bone strength, improve local osteoporosis and improve bone metabolism, and it is indicated that NAT10 can be used forconstructing a novel stem cell osteogenic material. Therefore, the method can provide a new treatment scheme for osteoporosis treatment.

The invention relates to a verification method for stimulating osteogenic differentiation of valvular interstitial cells by inorganic phosphate. The method comprises the following steps: respectivelyperforming osteogenic differentiation culturing on extracted rat valvular interstitial cells by using CON, IP-OIM and OIM and then extracting protein to prepare a protein sample; after ALP staining and alizarin red staining on three kinds of protein samples, evaluating an osteogenic differentiation degree after staining by using ALP activity detection and a relative calcium content determination method, and detecting expression changes of BMP-2, RhoA and Rock-1 through a WB method and an RT-PCR method respectively; with the si-RNA technology, respectively interfering the expression of BMP-2 and RhoA and observing the relationship of mutual changes between the BMP-2 and the RhoA and whether the BMP-2 and the RhoA have the effect of resisting osteogenic differentiation or not after interference; and studying the influence of IP-OIM on SMAD1/5/9 phosphorylation as well as a mutual relation between two paths of BMP-2/SMAD1/5/9 and RhoA/Rock-1. According to the invention, facts that calcification formation of valvular interstitial cells is caused by inorganic phosphate through BMP-2/smald1/5/9 and RhoA/Rock-1 signal pathways and the BMP-2/SMAD1/5/9 pathway is an upstream pathway of theRhoA/Rock-1 pathway in the valvular interstitial cell osteogenic differentiation process are determined; and a forward regulation effect is realized.

The invention discloses up-conversion nanoparticles and application thereof in light-operated induction of MSC (mesenchymal stem cell) cartilage differentiation and tracing imaging. According to the up-conversion nanoparticles, the surface of a mesoporous silicon layer is modified with cell-targeted polypeptide RGD. KGN and the up-conversion nanoparticles are stirred for reaction and centrifuged to obtain the KGN-loaded nano-composite. The nano-composite loaded with the KGN and MSC are co-incubated, and then the cells are irradiated by using near-infrared light to promote the nano-composite loaded with the KGN to release small drug molecules KGN to induce the MSC to be directionally differentiated into cartilage cells; and the differentiated MSC is traced and imaged through 545/647 nm fluorescence emitted by the up-conversion nanoparticles. The nano-composite disclosed by the invention has a cell targeting effect, and the drug KGN can be released only when 980nm near-infrared illumination exists outside, so that cartilage differentiation of stem cells is induced; and the cell imaging can be traced for a long time, and the positioning is provided for the MSC in the transplantation body.

The invention provides a method for improving the osteogenesis ability of mesenchymal stem cells, which comprises the following steps: inoculating the mesenchymal stem cells into an alpha-MEM culturemedium containing 10% of fetal calf serum, culturing, digesting and subculturing by 0.2% of pancreatin when the fusion degree of the mesenchymal stem cells is 80-85%, inoculating the obtained mesenchymal stem cells into an alpha-MEM culture medium containing 10% of fetal calf serum for culture, and adding osteogenesis induction liquid and a metformin aqueous solution for induction when the densityof the mesenchymal stem cells is greater than 90% for induction for 14-21 days. The metformin acts on the mesenchymal stem cells, alizarin red staining results show that the metformin can significantly improve the calcium mineralization nodule degree of the cells, and it is indicated that the metformin has a significant induction effect on mesenchymal stem cell osteogenic differentiation, the metformin can significantly improve the expression of the mesenchymal stem cell osteogenic differentiation related genes SIRT1, ALP, COL1A1, RUNX2 and BGLAP, and the improvement of the osteogenic differentiation capacity of the mesenchymal stem cells is of great significance to stem cell transplantation and bone biology research.

The invention discloses a method for establishing an osteoarthritis osteoclast-like cell model of mesenchymal stem cells after directional cartilage differentiation through a two-step method. The method comprises the steps that firstly, the mesenchymal stem cells are induced to be subjected to directional differentiation into articular cartilage cells, and then the articular cartilage cells are induced by adopting IL-1beta in-vitro induction to establish the osteoarthritis model. According to the method, the two-step method is used for establishing the osteoarthritis model after directional cartilage differentiation for the first time, and by exploring the cartilage cell morphology and expression change of phenotype genes aggrecan and Co12alpha1, the optimal use concentration and cell induction time of a solution are determined. The method is easy to operate and low in cost and can be applied to related studies such as cell quality evaluation of the mesenchymal stem cells after directional cartilage differentiation, early warning of easy infection of adult osteoarthritis, verification of osteoarthritis drug action targets and screening of drug toxicity/drug functions.